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ABSTRACT 
Objective: Statins being the first choice drug for dyslipidaemia, the quest for better one among all has always been and still a question for research 
in the field of medicine. Objective The objective of our study was to find out the best statin among the two, Atorvastatin and Rosuvastatin, in terms of 
efficacy and safety; alone or in combination with Fenofibrate for the management of dyslipidaemia.  
Methods: This was an open label, randomized, parallel group, prospective comparative study, carried out in patients in two groups treated with 
Atorvastatin and Rosuvastatin (10mg each) for 6 weeks, after which Fenofibrate (67mg) was added as an add on therapy in either group for the 
next 4 weeks before and after treatment.  
Results: After the treatment, the TC, TG, LDL- C, HDL- C and Non HDL- C were comparable between two groups. The changes in the levels of TC were 
-15.90±5.16 (-8.53%) vs -20.70±4.83 (-11.32%) respectively in groups treated with Atorvastatin (group I) and Rosuvastatin (group II). Changes in 
TGs were -11.60±4.16 (-7.46%) vs -15.10±5.18 (-9.99%), respectively; change in LDL- C were -16.90±3.58 (-15.31%) vs -13.0±3.04 (-11.56%) 
respectively; change in HDL- C were +6.75±0.86 (+18.72%) vs +9.0±1.22 (+23.72%) respectively in each group; change in Non HDL- C were found to 
be -6.90±4.83 (-4.4%) vs -7.8±4.78 (-5.05%) respectively in groups I and II. After the addition of Fenofibrate (67mg) there were no significant 
changes in the different parameters of serum lipid profile.  
Conclusion: The result of our study suggests that Rosuvastatin (10mg) was more efficacious than Atorvastatin (10mg) in lipid lowering effect and 
HDL- C raising effect but should be used with great caution and care in patients with uncontrolled hyperglycaemia and in those with compromised 
hepatic status. Further addition of Fenofibrate (67mg) didn’t make any significant difference in the result. 
Keywords: Statins, Cardiovascular events, Fibrates, Open label, Randomized, HMG Co-A reductase. 
 
INTRODUCTION 
Although numerous studies have been done in the past and are still 
going on, regarding the efficacy, safety and potency of statins 
especially Atorvastatin and Rosuvastatin, the two most recently 
introduced among all, after the advent of Lovastatin in clinical 
practice in the 1980’s and are ranked amongst the most widely 
studied and prescribed classes of medicine in the world. Today, the 
two most frequently prescribed and studied statins among all are 
Rosuvastatin and Atorvastatin and there is enough literature 
available regarding their safety and efficacy, and both of them have 
got their own list of advantages and superiorities over all other 
previously introduced statins as well as over each other. 
We designed the open label, randomized study to compare the two 
statins in terms of efficacy and safety benefits and subsequently to 
optimize the best drug combination of statins along with 
Fenofibrate. Fibrates or fibric acid derivatives rank next to statins in 
the broad category of antihyperlipidaemic drugs and are often 
frequently prescribed as a dual combination therapy for the 
management of dyslipidaemias. Since today it is a globally 
established fact that dyslipidaemias are amongst the major risk 
factors for CVD (cardiovascular diseases) and death as its 
consequence [1]. In the past several large scale trials and studies 
have reported that the use of statins considerably reduces the risk of 
CVD and death and can be used for both the primary and secondary 
prevention of CVD [2–3]. Numerous large scale trials of statins in the 
past reported a significant reduction in relative risk of coronary 
events. Few studies of utmost importance among them are 4S study 
(Scandinavian Simvastatin Survival Study), LIPID (Long term 
Intervention with Pravastatin in Ischemic Disease) and HPS [6] 
(Heart Protection Study), which reported significant reduction in the 
relative risk for mortality by all causes due to CVD by 30%, 22% and 
13% respectively [4–6]. Patients with Diabetes Mellitus type II, 
hypertension in association with dyslipidaemia have an increased 
incidence of atherosclerotic vascular disease where synergistic effect 
for increased risk is attributable to dyslipidaemia [7–9]. The study 
was designed and conducted in Northern India at a tertiary care 
center for tropical diseases, keeping the fact in mind that very lesser 
number of studies have been done here regarding statins and with 
the objective to optimize the best of the two statins alone or in 
combination with Fenofibrate.  
Ethical approval 
This was an open label, randomized, parallel group, prospective 
study carried out at Out Patient Clinic of Rajendra Memorial 
Research Institute of Medical Sciences, Patna, Bihar, India with the 
approval of Institutional Ethical Committee. 
MATERIAL AND METHODS  
Materials 
A total of 213 patients were screened for recruitment in dietary run 
in period, out of which 164 patients, after providing written 
informed consent entered randomization into two groups of 79 and 
85 patients respectively. The subjects were men and women of age 
18 years and above. The patients recruited for randomization were 
first divided into 79 and 85 patients, received Atorvastatin and 
Rosuvastatin each 10mg respectively for a period of 6 weeks after 
which they were given add on therapy with Fenofibrate 67 mg 
nanoparticle tablets along with statins in both the groups for the 
next 4 weeks. The study was conducted from August 2013 to April 
2014. 
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Setting, inclusion and exclusion criteria 
This study was conducted at a tertiary care center for tropical 
diseases in Patna, Bihar, India. Patients of either gender of age 18 
years and above, diagnosed with Diabetes Mellitus II, Hypertension, 
history of CVD, Metabolic syndrome along with Dyslipidaemia as 
defined by National Cholesterol Education Programme Adult 
Treatment Panel III (NCEP ATP III) were included in the study. NCEP 
ATP III defines dyslipidaemia as Total cholesterol ˃ 200mg/dl, TGs 
(Triglycerides) ˃150mg/dl, LDL - C (Low Density Lipoprotein- 
Cholesterol) ˃100 mg/dl and HDL - C (High Density Lipoprotein- 
Cholesterol) ˂ 40 mg/dl. The patients with newly diagnosed 
dyslipidaemia only were included in the study. NCEP ATP III defines 
Metabolic syndrome as the presence of 3 or more of the following 
risk factors- (1) Increased waist circumference (˃102 cm for men 
and ˃88 cm for women) (2) Hypertriglyceridemia (˃150 mg/dl) (3) 
Low HDL levels (˂ 40 mg/dl for men and ˂50 mg/dl  for women) (4) 
Hypertension (≥130/85 mmHg) (5) Impaired fasting glucose (≥110 
mg/dl). Patients were excluded from enrolment into study if they 
met any of the following exclusion criteria- (1) Known 
contraindication or hypersensitivity to Statins or Fibrates (2) Known 
history or presence of renal or hepatic dysfunction (3) Thyroid 
dysfunction as well as (4) pregnant and lactating women (5) HIV, 
HBsAg and HCV positive were excluded from the study. Patients with 
history of tuberculosis confirmed by chest x-Ray PA view, sputum 
examination and IS6110-polymerase chain reaction (PCR) and other 
chronic diseases were excluded from the study [10–11].  
Statistical analysis 
Statistical analysis was done using the statistical software’s SPSS and 
graph pad prism. The raw baseline and demographic variables were 
analysed as the mean, standard deviation minimum and maximum 
values as well as the number and percentage of observations. The 
baseline and the follow up characteristics for continuous variables 
were compared using students’ test. 
RESULTS 
At the beginning of study 79 patients were included in group Ι 
(Atorvastatin group) and 85 patients were included in group ΙΙ 
(Rosuvastatin group), out of which 10 and 13 patients were lost to 
follow up from each group respectively after the first follow up and 
after the Fenofibrate add on follow up, 18 patients from group Ι 
(Atorvastatin+Fenofibrate) and 16 patients from group ΙΙ 
(Rosuvastatin+Fenofibrate) were lost to follow up during the second 
follow up period. 
Ι. Difference in Serum Lipid Profile and other parameters between 
baseline and treatment period after 6weeks is described below. 
At the beginning of study the baseline lipid profile were as follows; 
TC levels in group Ι and ΙΙ were 194.3±38.03 mg/dl and 193.2±33.22 
mg/dl respectively (p=0.84); the TGs levels were 161.3±26.40 mg/dl 
and 158.7±38.20 mg/dl respectively (p=0.61); the LDL-C levels were 
118.8±22.2 mg/dl and 118.9±21.10 mg/dl respectively (p= 0.91); 
the VLDL-C levels were 31.85±8.66 mg/dl and 33.76±8.792 mg/dl 
respectively (p=0.16); the HDL-C levels were 32.68±5.12 mg/dl and 
33.43±6.81 mg/dl respectively (p=0.42) and the non HDL-C levels 
were 160.1±32.85 mg/dl and 158.2±33.08 mg/dl respectively 
(p=0.71). The fasting plasma glucose levels were almost similar in 
both the groups and were 125.7±25.25 mg/dl and 126.7±22.2 mg/dl 
respectively (p=0.78). The blood urea nitrogen, serum creatinine, 
uric acid and SGPT levels were almost similar between the two 
groups; however group ΙΙ patients had a slightly higher aspartate 
transaminase (AST) levels than group Ι patients (30.11±5.65 Vs 
28.84±5.73 mg/dl; p=0.15). Also the high sensitivity C-reactive 
protein (HsCRP) levels were similar in both the groups (1.97±1.05 vs 
2.0±1.06; p=0.86). 
After the 6 week randomization period, the TC levels were found to 
be 178.4±21.13 mg/dl in group Ι and 172.5±24.16 mg/dl in group ΙΙ; 
(p=0.12), TG levels were 140.7±23.9 mg/dl and 143.6±23.70 mg/dl 
respectively; (p=0.13), the LDL-C levels were 101.9±21.22 mg/dl 
and 105.9±16.20 mg/dl respectively (p=0.20), the VLDL-C levels 
were 29.3±5.76 mg/dl and 31.02±7.64 mg/dl respectively (p=0.13), 
the HDL-C levels were 39.43±8.4 mg/dl and 42.43±8.5 respectively 
(p=0.014٭); while the non-HDL-C levels were 153.2±24.73 mg/dl 
and 150.4±25.5 mg/dl respectively (p=0.50) (Table 1). 
The fasting blood glucose levels after the six week randomization 
period were found to be 109.3±19.44 mg/dl and 115.1±18.42 mg/dl 
respectively in group Ι and ΙΙ (p=0.07). However the uric acid, serum 
creatinine and alanine transaminase (ALT) levels were almost 
similar to their baseline values but the AST levels were found to be 
slightly raised from 30.11±5.65 vs 31.54±5.14 mg/dl. The HsCRP 
levels were found to be slightly lowered than their baseline values 
(Table 2). The mean ± standard deviation and the percentage change 
in the lipid parameters after 6 week treatment period were found to 
be as follows: 
 
Table 1: Patient demographics and baseline characteristics 
Characteristics Atorvastatin (10 mg) (79) (I) Rosuvastatin (10 mg) (85) (II) ‘p’ VALUE 
Age-years 52.04±8.6 54.0±9.35 0.15 
Age-Range 37-77 36-78  
Sex-no. (%)    
Male 47(59.5) 52(61.2)  
Female 32(40.5) 33(38.8)  
Weight-kg 71.33±9.13 69.4±7.83 0.14 
Height-cm 165.0±7.72 163.15±7.64 0.12 
BMI- (kg/mP2P) 26.45±3.27 26.6±3.29 0.77 
Smoking status- no. (%)    
Never 37(46.9) 42(49.4)  
Former 24(30.3) 29(29.1)  
Current 18(22.8) 14(16.4)  
Alcoholic status- no. (%)    
Heavy 13(16.4) 17(20.0)  
Moderate 20(25.3) 19(22.3)  
Abstinent 46(58.2) 49(57.7)  
Previous CVD history- no. (%) 26(32.9) 31(36.4)  
Metabolic Syndrome- no. (%)    
Abdominal obesity 38(48.1) 34(40.0)  
Hypertriglyceridemia 39(49.3) 41(48.2)  
Low HDL-C 66(83.6) 70(82.3)  
Blood Pressure ≥ 130/85 24(30.3) 21(24.7)  
Fasting blood glucose ≥ 110 mg/dl 50(63.2) 57(67.0)  
Blood Pressure- mmHg    
Systolic 127.3±9.4 127.5±11.6 0.90 
Diastolic 83.57±6.1 82.53±6.4 0.29 
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Blood Glucose- mg/dl    
Fasting 125.7±25.2 126.7±22.2 0.78 
Post Prandial 168.2±38.1 167.2±27.7 0.84 
Blood Urea Nitrogen-mg/dl 25.49±7.8 26.02±7.8 0.66 
Creatinine- mg/dl 1.17±0.3 1.23±0.4 0.26 
Uric Acid- mg/dl 4.45±1.5 4.4±1.6 0.85 
Liver Enzymes- U/L    
AST 28.9±5.8 30.11±5.7 0.15 
ALT 35.0±6.9 35.18±7.5 0.93 
Serum Lipid Profile- mg/dl    
Total- C 194.3±38.0 193.2±33.2 0.84 
TG 161.3±26.4 158.7±38.2 0.61 
LDL- C 118.8±22.2 118.9±21.1 0.97 
VLDL- C 31.85±8.7 33.8±8.8 0.16 
HDL- C 32.7±5.1 33.4±6.9 0.42 
Non HDL- C 160.1±32.9 158.2±33.0 0.71 
Hs CRP Levels- no.(%)    
Low risk (˂1.0mg/l) 20(25.3) 26(30.5)  
Average risk (1.0-3.0mg/l) 46(58.2) 49(57.7)  
High risk (˃3.0mg/l) 13(16.4) 10(11.8)  
Average levels 1.98±1.0 2.0±1.0 0.86 
Medications- no. (%)    
Metformin (Biguanides) 29(36.7) 36(42.3)  
Sulfonylureas  19(24.1) 33(38.9)  
Alpha Glucosidase Inhibitors 11(13.9) 09(10.6)  
Thiazolidinediones 06(7.5) 03(3.6)  
Diuretics (Thiazides) 16(20.2) 12(14.1)  
Angiotensin Converting Enzyme Inhibitors(ACEIs) 17(21.6) 20(23.6)  
Angiotensin Receptor Blockers(ARBs) 25(31.7) 19(22.3)  
Calcium Channel Blockers (CCBs) 23(29.1) 28(32.9)  
Beta Blockers (BBs) 21(26.6) 26(30.6)  
Dipeptidyl Peptidase 4 Inhibitors (DPP4Is) 04(5.0) 03(3.6)  
Bronchodilators 09(11.3) 07(8.2)  
5 Alpha Reductase Inhibitors 02(2.6) 05(5.9)  
Values are presented as mean±SD, unless stated otherwise., SD, Standard deviation of the mean, AST, Aspartate transaminase; ALT, Alanine 
transaminase., HsCRP, High Sensitivity C - reactive protein., BMI- Body Mass Index (weight in kilograms divided by square of height in meters). 
 
The change in Total-C levels in group Ι and ΙΙ were -15.90±5.16 (-
8.53%) and -20.70±4.83 (-11.32%) mg/dl respectively; in TG levels 
were -11.60±4.16 (-7.46%) and -15.10±5.18 (-9.9%) respectively; in 
LDL-C levels were -16.90±8.58(-15.31%) and -13.0±3.04 (-11.56) 
mg/dl respectively; in VLDL- C levels were -2.58±1.22 (-8.34%) and 
-2.74±1.33 (-8.45%) mg/dl respectively; in LDL-C levels were 
6.75±0.86(18.72%) and 9.0±1.22(23.72%) mg/dl respectively; in 
non HDL-C levels were -6.90±4.836(-4.4%) and -7.8±4.75(-5.05%) 
respectively in both the group Ι and ΙΙ. Change in fasting blood 
glucose levels after the randomization period were -16.40±3.75 (-
13.95%) in group Ι which was higher than the corresponding group 
ΙΙ with a change of -11.60±3.29 (-9.59%). 
 






Serum Lipid Profile- mg/dl    
Total- C 178.4±21.1 172.5±24.1 0.12 
TG 149.7±23.9 143.6±23.7 0.13 
LDL-C 101.9±21.2 105.9±16.2 0.20 
VLDL- C 29.3±5.8 31.0±7.7 0.13 
HDL- C 39.4±5.4 42.4±8.5 0.01* 
Non HDL- C 153.2±24.8 150.4±25.5 0.5 
Blood glucose-mg/dl    
Fasting 109.3±19.4 115.1±18.4 0.07 
Uric Acid- mg/dl 4.48±1.5 4.21±1.5 0.30 
Creatinine- mg/dl 1.18±0.3 1.27±0.4  0.18 
Liver Enzymes- U/L    
AST 27.88±5.4 31.6±5.1  ** 
ALT 34.9±7.2 35.9±7.5 0.45 
Blood Pressure- mmHg    
Systolic 124.5±6.5 123.8±7.5 0.55 
Diastolic 81.45±6.2 80.29±6.1 0.26 
HsCRP 1.87±0.9 1.90±1.0 0.87 
Values are presented as mean±SD, unless stated otherwise., SD, Standard deviation of the mean., AST, Aspartate transaminase; ALT, Alanine 
transaminase., HsCRP, High Sensitivity C - reactive protein., *p ˂ 0.05 , **p ˂ 0.01 . The AST and ALT levels in group Ι decreased by -0.96±0.92 (-
3.38%) and -0.1±1.17 (-0.28%) respectively, where as in group ΙΙ, the AST and ALT levels were increased by 1.43±0.86 (4.63%) and 0.74±1.21 
(2.08%) respectively corresponding to group of patients treated with Rosuvastatin (10mg) (Table 3). 
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Table 3: Difference in parameters between the baseline and treatment period after six weeks 
Characteristics Atorvastatin(69) 
(I) Change 
Mean± SD (%) 
Rosuvastatin(72) 
(II) Change 
Mean± SD (%) 
Serum Lipid Profile- mg/dl   
TOTAL- C -15.9±5.16 (-8.53%) -20.7±4.83 (-11.32%) 
TG -11.6±4.17 (-7.45%) -15.1±5.18 (-9.96%) 
LDL- C -16.9±3.58 (-15.31%) -13.0±3.04 (-11.56%) 
VLDL- C -2.55±1.22 (-8.34%) -2.74±1.33 (-8.45%) 
HDL- C +6.75±0.86 (+18.72%)  +9.0±1.22 (+23.72%) 
NON HDL- C -6.90±4.83 (-4.4%) -7.8±4.78 (-5.0%) 
Blood Glucose- mg/dl   
Fasting -16.4±3.74 (-13.95%) -11.60±3.29 (-9.59%) 
Uric Acid- mg/dl +0.03±0.25 (+0.69%) -0.19±0.25 (-4.41%) 
Creatinine- mg/dl +0.02±0.06 (+1.70%)  +0.04±0.06 (+3.32%) 
Liver Enzymes- U/L   
AST -0.96±0.92 (-3.38%) +1.43±0.86 (+4.63%) 
ALT -0.1±1.17 (-0.28%) +0.74±1.21 (+2.08%) 
Blood Pressure- mmHg   
Systolic -2.80±1.35 (-2.22%) -3.70±1.59 (-2.94%) 
Diastolic -2.12±1.02 (-2.56%) -2.24±1.01 (-2.75%) 
HsCRP -0.10±0.15 (-5.5%) -0.10±0.16 (-5.12%) 
Values are presented as change in mean±SD, (%)., II. Differences in parameters following Fenofibrate add on after the next four weeks is described 
below. 
 
The changes in serum lipid profile after the addition of Fenofibrate 
(67 mg) in both the groups were found to be; the Total- C levels 
were changed from 178.4± 21.13 mg/dl to 168.2± 27.91 mg/dl with 
a change of -10.20±4.47 (-5.88%) in group I and from 172.5±24.16 
mg/dl to 162.3±26.87 mg/dl with a change of -10.2±4.52 mg/dl (-
6.09%) in group II; the TG levels changed from 149.7±23.9 to 
140.9±26.57 mg/dl (change -8.80±4.62; -6.05%) and from 
143.6±23.7 to 131.5±26.6 mg/dl (change -12.1±4.45; -8.79%) 
respectively. The LDL- C levels changed from 101.9±21.22 mg/dl to 
92.5±16.97 mg/dl in group I (change -9.39±3.6; -9.66%) and from 
105.9±16.20 to 93.77±12.8 mg/dl (change -12.13±2.64; -12.15%) in 
group II. The VLDL- C levels changed from 29.30±5.76 mg/dl to 
26.21±4.33 mg/dl (change -3.09±0.96; -11.13%) and from 
31.02±7.69 mg/dl to 28.45±7.37 mg/dl (change -2.57±1.34; -8.64%), 
respectively in both the groups.  
However the change in HDL- C levels were almost similar and were 
found to be increased in both the groups; in group I HDL- C levels 
increased from 39.43±5.4 mg/dl to 41.53±5.98 with a change of 
+2.1±1.04 mg/dl (+5.18%); where as in group II the levels increased 
from 42.43±8.5 mg/dl to 44.58±7.38 mg/dl with a change of 
+2.15±1.43 mg/dl (+4.94%). The Non HDL– C levels changed from 
153.2±24.73 mg/dl to 151.2±24.9 mg/dl (change–2±4.58; - 1.31%) 
and from 150.4±25.5 mg/dl to 147.3±23.9 mg/dl (change –
3.10±4.43; -2.08%) respectively in groups I and II. However, the 
fasting blood glucose levels changed more slightly in group I, from 
109.3±19.4 mg/dl to 97.98±15.06 mg/dl, than in group II where the 
levels changed from 115.1±18.42 mg/dl to 105.4±20.4 mg/dl, with a 
mean ±SD (%) change of – 11.32±3.27 (- 10.92%) mg/dl and -
9.7±3.4 (-8.79%) mg/dl respectively in groups I and II (Table 4–5). 
 
Table 4: Randomized open label treatment as an add fenofibrate after four weeks 
Characteristics Atorvastatin+ Fenofibrate(10 mg + 67 
mg)(51) 
Rosuvastatin+ Fenofibrate(10 mg + 67 
mg)(56) 
‘p’ Value 
Serum Lipid Profile- mg/dl    
Total- C 168.2±28.0 162.3±26.9 0.26 
TG 140.9±26.5 131.5±26.7 0.07 
LDL- C 92.51±16.8 93.8±12.9 0.66 
VLDL- C 26.21±4.3 28.45±7.3 0.06 
HDL- C 41.53±6.0 44.59±7.4 0.02 
Non HDL- C 151.2±25.0 147.3±23.8 0.4 
Blood Pressure- mmHg    
Systolic  122.5±6.2 120.8±7.0 0.16 
Diastolic 80.3±6.3 80.0±6.0 0.74 
Blood Glucose- mg/dl    
Fasting 98.0±15.0 105.4±20.4 0.03* 
Values are presented as mean±SD, unless stated otherwise. SD, Standard deviation of the mean, *p ˂ 0.05  
 
DISCUSSION 
The result of our study suggests that the efficacy of Rosuvastatin (10 
mg) was more than Atorvastatin (10 mg) in terms of Total – C and 
TG lowering effect as well as HDL– C increasing effect (HDL– C raised 
by +23.7%), HDL- C raising effect was a more considerable 
phenomenon observed in case of patients treated with Rosuvastatin 
(10mg) than in patients treated with Atorvastatin (10mg); (HDL- C 
+18.7%). However as far as LDL–C lowering effect is concerned, 
Atorvastatin (10mg) was slightly more efficacious than Rosuvastatin 
(10mg); (LDL- C reduced by –15.3% vs - %11.5, respectively).  
In case of VLDL- C and Non HDL- C lowering effect the efficacy of 
both the statins was almost similar and their results made no 
significant differences in the effect. However in case of blood glucose 
lowering effect, better control over fasting glucose levels was 
achieved in group of patients treated with Atorvastatin when 
compared to patients treated with Rosuvastatin; -13.95% vs–9.5% 
respectively. In a randomized control trial, it was found that 
Rosuvastatin has been found to have an association with significant 
risk for the causation of DM type II [12]. Comparatively inferior 
control of Rosuvastatin over blood glucose levels somewhere could 
be possibly attributable to its DM type II causing effect. As far as the 
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hepatic enzymes are concerned, the results of the effects were 
significantly interesting; where on one hand, the AST and ALT levels 
were found to be reduced in patients treated with Atorvastatin by -
1.61% and -1.30% respectively, while on the other hand the levels of 
these hepatic enzymes were found to be raised by + 4.63% and + 
2.08% respectively in case of patients treated with Rosuvastatin (10 
mg), which could be referred to the phenomenon of ‘transaminitis’, 
observed in patients treated with Rosuvastatin, where slight rise in 
the levels of hepatic enzymes was noted [13]. It is interesting to note 
that the phenomenon here in this study was observed only in case 
with Rosuvastatin, but generally ‘transaminitis’ is associated with all 
the other statins as well. Therefore by keeping in mind the effects of 
both the statins over liver enzymes, it is suggested to prefer 
Atorvastatin in clinical practice, only if the hepatic status of a patient 
is compromised, otherwise Rosuvastatin is a better available option 
in patients with uncompromised hepatic status. 
 











TOTAL- C -10.2±4.47 (-5.88%) -10.2±4.52 (-6.09%) 
TG -8.8±4.62 (-6.05%) -12.10±4.45 (-8.79%) 
LDL- C -9.3±3.6 (-9.66%) -12.13±2.64 (-12.15%) 
VLDL- C -3.1±0.96 (-11.13%) -2.57±1.34 (-8.64%) 
HDL- C +2.1±1.04 (+5.18%) +2.15±1.43 (+4.94%) 
NON HDL-c -2.0±4.58 (-1.31%) -3.10±4.43 (-2.08%)  
Blood Pressure- mmHg   
Systolic -2.0±1.18 (-1.61%) -3.1±1.30 (-2.53%) 
Diastolic -1.06±1.15 (-1.31%) -0.29±1.08 (-0.36%) 
Blood Glucose- mg/dl   
Fasting -11.32±3.27 (-10.92%)  -9.7±3.44 (-8.79%) 
Values are presented as change in mean±SD, (%). 
 
Add on therapy with Fenofibrate (67mg) made no significant 
differences in either groups and the efficacy of both of the 
combination therapies were found to be almost similar, except for 
the TG lowering effect which was observed more in patients treated 
with Rosuvastatin and Fenofibrate (TG–6.0% Vs–8.7%) respectively. 
Slightly better control over fasting blood glucose levels was found in 
Atorvastatin group comparable to Rosuvastatin group; - 11.32% vs–
9.7% respectively. Therefore it is evident by the results of the study 
to prefer Rosuvastatin (10mg) over Atorvastatin (10mg) for the 
achievement of better controls over serum lipid levels, except in 
patients with considerably uncontrolled blood glucose levels where 
Atorvastatin is a better choice for control of dyslipidaemias without 
compromised blood glucose status. Addition of Fenofibrate in either 
group made no significant differences in blood glucose lowering 
effect and was the same in case of statins alone (more with 
Atorvastatin). Rosuvastatin can be preferred over Atorvastatin in 
case where the hepatic status of the patient is not compromised; 
otherwise Atorvastatin can be a drug of choice over Rosuvastatin as 
well as over all other statins. Also it would be important enough to 
mention that the low doses of these statins are efficient enough for 
the management of dyslipidaemias in order to have a better control 
over serum cholesterol levels and no such requirement of higher 
doses of statins is felt, since it has already been concluded in few 
studies that Asians in general require low doses of statins than 
Caucasians for the management of dyslipidaemias, therefore low 
doses of statins are well enough to serve the desired purpose [14]. 
CONCLUSION 
The result of our study conclude that Rosuvastatin (10mg) is more 
efficacious than Atorvastatin (10mg) in cholesterol lowering effect 
and HDL- C raising effect, but should be prescribed cautiously in 
patients with uncontrolled blood glucose levels and in patients with 
compromised hepatic status, otherwise Atorvastatin (10mg) is a 
better option to be preferred upon. Addition of Fenofibrate (67mg) 
didn’t made any significant differences in the results and should only 
be considered in cases of uncontrolled hypertriglyceridemia where 
better control rates are not efficient enough to be achieved by statins 
alone. 
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